Literature DB >> 26735786

Human mu opioid receptor gene polymorphisms and vulnerability to substance abuse.

W H Berrettini1, M R Hoehe1, T N Ferraro1, P A Demaria1, E Gottheil1.   

Abstract

Two polymorphisms of the human mu opioid receptor gene are described. A non-coding region polymorphism (G to T) occurs at nucleotide 175 preceding the initiation of translation. A coding polymorphism in exon 1 (C to T) at nucleotide 229 changes an alanine residue to a valine residue. Frequencies of these polymorphisms were examined in groups of cocaine and/or opioid dependent individuals and matched controls. There were no significant differences between groups, although a trend (p= 0.05) towards a higher frequency of the 229 valine allele was observed in the substance abuse group, suggesting a need for large, well-controlled studies of this polymorphism in severe substance abusers.

Entities:  

Year:  1997        PMID: 26735786     DOI: 10.1080/13556219772598

Source DB:  PubMed          Journal:  Addict Biol        ISSN: 1355-6215            Impact factor:   4.280


  8 in total

1.  A C17T polymorphism in the mu opiate receptor is associated with quantitative measures of drug use in African American women.

Authors:  Howard A Crystal; Sara Hamon; Matthew Randesi; Judith Cook; Kathryn Anastos; Jason Lazar; Chenglong Liu; Leigh Pearce; Elizabeth Golub; Victor Valcour; Kathleen M Weber; Susan Holman; Ann Ho; Mary Jeanne Kreek
Journal:  Addict Biol       Date:  2010-11-11       Impact factor: 4.280

2.  [Are polymorphisms in the mu-opioid receptor important for opioid therapy?].

Authors:  J Lötsch; R Freynhagen; G Geisslinger
Journal:  Schmerz       Date:  2005-10       Impact factor: 1.107

Review 3.  Genetic variability of pain perception and treatment--clinical pharmacological implications.

Authors:  Jörn Lötsch
Journal:  Eur J Clin Pharmacol       Date:  2011-02-23       Impact factor: 2.953

4.  The untranslated region of (mu)-opioid receptor mRNA contributes to reduced opioid sensitivity in CXBK mice.

Authors:  K Ikeda; T Kobayashi; T Ichikawa; T Kumanishi; H Niki; R Yano
Journal:  J Neurosci       Date:  2001-02-15       Impact factor: 6.167

5.  A6V polymorphism of the human μ-opioid receptor decreases signalling of morphine and endogenous opioids in vitro.

Authors:  Alisa Knapman; Marina Santiago; Mark Connor
Journal:  Br J Pharmacol       Date:  2015-03-17       Impact factor: 8.739

Review 6.  Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives.

Authors:  Jörn Lötsch; Carsten Skarke; Jürgen Liefhold; Gerd Geisslinger
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 7.  OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models.

Authors:  Stephen D Mague; Julie A Blendy
Journal:  Drug Alcohol Depend       Date:  2010-01-13       Impact factor: 4.492

Review 8.  Genes associated with addiction: alcoholism, opiate, and cocaine addiction.

Authors:  Mary Jeanne Kreek; David A Nielsen; K Steven LaForge
Journal:  Neuromolecular Med       Date:  2004       Impact factor: 3.843

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.